Can a psoriasis drug heal these stubborn skin ulcers?

NCT ID NCT06563323

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests guselkumab (Tremfya), a drug already used for psoriasis, in 17 adults with pyoderma gangrenosum—a rare disease that leads to painful, hard-to-heal skin ulcers. Participants receive injections every 4 weeks for 28 weeks. Researchers will check if ulcers heal completely by week 32, and also track improvement at earlier time points.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
guselkumab (Tremfya)
What this could lead to
If successful, this could provide a new treatment option for pyoderma gangrenosum, helping heal painful skin ulcers and reducing the need for steroids.
What could go wrong
This is a small, early-phase trial with only 17 participants, so results may not apply to everyone. The drug may not work for all patients, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PYODERMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ohio State Dermatology

    RECRUITING

    Columbus, Ohio, 43215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Oregon Health and Science University

    NOT_YET_RECRUITING

    Portland, Oregon, 97239, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.